

FORM PTO 1449 (modified)


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 14, 1999

ATTY DOCKET NO.
00292/Case 16.75.US (37)
IPD/9909-060SERIAL NO.
09/375,514APPLICANT
Luc UYLENBROECK et al.FILING DATE
August 17, 1999

GROUP

1635



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
mmS	A	4,525,358	6/85	Baltes et al.	514	255	
mmS	B	5,478,941	12/95	Cossement et al.	544	383	
	C						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
mmS	D	0 617 028	9/94	EP			Corresponds to Ref AB
	E	94/06430	3/94	WO			Corresponds to Ref AA
	F	0 058 146	8/82	EP			
	G	2 311 940	1/97	GB			
	H						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

mmS	I	K. P. PAUL, "ETAC: an Update", International Journal of Immunopathology and Pharmacology, Vol. 10, No. 2, pp. 127-128, 1997.					
	J	U. WALN, "Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC", Pediatric Allergy and Immunology, Vol. 9, No. 3, pp. 116-124, August 1998.					
	K	L. FASCE et al., "Cetirizine Reduces ICAM-1 on Epithelial Cells during Nasal Minimal Persistent Inflammation in Asymptomatic Children with Mite-Allergic Asthma", Int. Arch. Allergy Immunol. Vol. 109, No. 3, pp. 272-276, 1996.					
	L	A. Brik et al., "Effect of cetirizine, a new histamine H ₁ antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma", Vol. 80, No. 1, pp. 51-56, 1987.					
	M	J.O. WARNER et al, "Determinants of total and specific IgE in infants with atopic dermatitis", Pediatric Allergy and Immunology, Vol. 8, pp. 177-184, November 1997.					
	N	J.H. DIJKMAN et al., "Prophylactic treatment of grass pollen-induced asthma with cetirizine", Clinical and Experimental Allergy, Vol. 20, pp. 483-490, September 1990.					
EXAMINER <i>mm Schmidt</i>				DATE CONSIDERED 6-18-01			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 14, 1999

ATTY DOCKET NO.
00292/Case 16.75.US (37)
IPD/9909-060SERIAL NO.
09/375,514APPLICANT
Luc UYLENBROECK et al.FILING DATE
August 17, 1999

GROUP

1635



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AF						
	AG						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

mm-5	AH	C. DE VOS et al., "Antihistamines and allergic asthma", Allergie et Immunologie, Vol. 23, No. 9, pp. 396-401, November 1991.
	AI	D. TASHKIN et al., "Cetirizine inhibition of histamine-induced bronchospasm", Vol. 59, pp. 49-52, December 1987.
	AJ	G. Bruttman et al., "Protective effect of cetirizine in patients suffering from pollen asthma", Annals of Allergy, Vol. 64, pp. 224-228, February 1990.
	AK	H. REDIER et al., "Inhibitory effect of cetirizine on the bronchial eosinophil recruitment induced by allergen inhalation challenge in allergic patients with asthma", Journal of Allergy and Clinical Immunology, Vol. 90, No. 2, pp. 215-224, August 1992.
	AL	J.B. WASSERFALLEN et al., "Effect of cetirizine, a new H ₁ antihistamine, on the early and late allergic reactions in a bronchial provocation test with allergen", Journal of Allergy and Clinical Immunology, Vol. 91, No. 6, pp. 1189-1197, June 1993.
	AM	J.A. GRANT et al., "Safety and efficacy of cetirizine (CET) in the prophylactic management of patients with seasonal allergic rhinitis (SAR) and asthma", Vol. 91, No. 1, p. 197, March 12-17, 1993.
✓	AN	
EXAMINER	DATE CONSIDERED 6-18-01	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)


U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: September 14, 1999

ATTY DOCKET NO.
00292/Case 16.75.US (37)
IPD/9909-060SERIAL NO.
09/375,514APPLICANT
Luc UYLENBROECK et al.FILING DATE
August 17, 1999

GROUP

1639



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BC						
	BD						

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

mm5	BE	"Medical researchers aim at fundamental better protection and treatment of the atopic child", ETAC Science, pp. 1-8, January 1994.
	BF	"Asthma prevention in risk children: Cetirizine", pp. 61-62, 1995.
	BG	I. Trieloff, "Early treatment of the atopic child", pp. 390-391, 1995.
	BH	"The role of early intervention in childhood asthma therapy", pp. 8224-827, 1998.
	BI	E. Bidat et al., "The treatment of childhood asthma", pp. 3021-3026, 1991.
	BJ	L. Businco et al., "From atopic dermatitis to asthma", pp. 477-481, 1997.
	BK	B. Schwarz, "Treatment with cetirizine also for children", p 34, 1993.
	BL	S. Matsubara et al., "Effect of betotastine basilate on experimental asthma model in guinea pigs", pp. 31-36, 1997.
EXAMINER	DATE CONSIDERED 6-18-01	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
3335-075-55-CONTSERIAL NO.
09/375,514

APPLICANT

John C. REED

LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

FILING DATE

August 17, 1999

GROUP

UNASSIGNED

1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
<i>mms</i>	AA	4,999,290	03/12/91	LEE			03/31/88
	AB	5,015,568	05/14/91	TSUJIMOTO et al.			07/09/86
	AC	5,098,890	03/24/92	GERWITZ			10/27/89
	AD	5,149,628	09/22/92	CROCE			11/15/89
	AE	5,202,429	04/13/93	TSUJIMOTO et al.			03/19/91
	AF	5,459,251	10/17/95	TSUJIMOTO et al.			
	AG	5,585,479	12/17/96	HOKE et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
<i>mms</i>	AH	WO 94/27426	12/08/94	PCT/WIPO	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>mms</i>	AI	Toshiyuki Miyashita et al., CANCER RESEARCH, Vol. No. 52, pp. 5407-5411, Oct. 1, 1992
	AJ	Toshiyuki Miyashita et al., BLOOD, Vol. No. 81, pp. 151-157, Jan. 1, 1993
	AK	J. C. Reed et al., ANNALS OF ONCOLOGY, 1993, Page Nos. 61-65.
	AL	F. E. Cotter et al., ONCOGENE, Vol. No. 9, pp. 3049-3055, Oct. 1994
	AM	Shinichi Kitada et al., ANTISENSE RESEARCH AND DEVELOPMENT, Vol. 4, pp. 71-79, Summer 1994
	AN	Shinichi Kitada et al., ANTISENSE RESEARCH AND DEVELOPMENT, Vol. 3, pp. 157-169, Summer 1993
	AO	Reed et al., CANCER RES., 50, p. 5656, 1990
	AP	Williams, CELL 65, p.1097, 1991
	AQ	Strasser et al., CELL 67, p. 889, 1991
	AR	PATENT COOPERATION TREATY (PCT) INTERNATIONAL SEARCH REPORT dated Jan. 12, 1995
	AS	C. Paoletti, "ANTI-SENSE OLIGONUCLEOTIDES AS POTENTIAL ANTITUMOUR AGENTS: PROSPECTIVE VIEWS AND PRELIMINARY RESULTS," ANTI-CANCER DRUG DESIGN, Vol. 2, pp.325-331, 1988
	AT	Stein et al., "OLIGODEOXYNUCLEOTIDES AS INHIBITORS OF GENE EXPRESSION: A REVIEW," CANCER RESEARCH, Vol. 48, pp. 2659-2668, May 15, 1988

EXAMINER

M. Schmitt

DATE CONSIDERED

6/15/01

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

3335-075-55-CONT

09/375,514

APPLICANT

John C. REED

LIST OF REFERENCES CITED BY APPLICANT
(Use Several Sheets if Necessary)

FILING DATE

GROUP

August 17, 1999

UNASSIGNED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

mas	AU	Eugen Uhlmann et al., "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE," CHEMICAL REVIEWS, Vol. 90, No. 4, pp. 544-584, June 1990
	AV	Tsujimoto, Y., et al., PROC. NATL. ACAD. SCI. USA, Vol. 83, pp. 5214-5218, July 1986
	AW	Negrini, M., et al., CELL, Vol. 49, pp. 455-463, 1987
	AX	Reed, J., et al., SCIENCE, Vol. 236, pp. 1295-1299, June 5, 1987
	AY	Orkin SH, et al., "REPORT AND RECOMMENDATIONS OF THE PANEL TO ASSESS THE NIH INVESTMENT IN RESEARCH ON GENE THERAPY"

EXAMINER

M. Schmidt

DATE CONSIDERED

6/19/01

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.